<DOC>
	<DOCNO>NCT01018914</DOCNO>
	<brief_summary>To compare safety efficacy Prograf速 Myfortic速 Advagraf速 extend release tacrolimus Myfortic速 de novo liver transplant recipient .</brief_summary>
	<brief_title>A Study Compare Safety Efficacy Prograf + Myfortic Advagraf + Myfortic Liver Transplantation Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient primary liver transplant recipient Female patient child bear potential must negative urine serum pregnancy test within 7 day prior transplant Patient fully inform signed IRB approve informed consent form willing able follow study procedure Patient must receive 1st dose study drug within 24 hour pretransplantation Patient previously receive receive organ transplant liver Patient currently require dialysis Patient receive liver transplant nonheart beat donor Patient receive ABO incompatible donor liver Recipient donor know seropositive human immunodeficiency virus ( HIV ) Patient fulminant hepatic failure , unless hemodynamically stable Patient uncontrolled concomitant infection , systemic infection require treatment ( except viral hepatitis ) , unstable medical condition could interfere study objective Patient currently take take investigational drug 30 day prior transplant Patient know hypersensitivity tacrolimus , entericcoated mycophenolate sodium corticosteroid Patient pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Prograf</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Myfortic</keyword>
</DOC>